王琪;赵红;黄燕;付于;

• 1:天津中医药大学
• 2:天津中医药大学第一附属医院
• 3:广东省中医院

摘要(Abstract)：

脑卒中是一种严重危害人类健康的全球性问题,脑卒中二级预防具有重要意义。学者们从多方面进行了研究,例如抗血小板治疗,抗凝治疗,控制高血压,控制血糖、血脂异常,改善生活方式等。目前总结出缺血性脑卒中二级预的ABCDE策略,可以有效的减少血管事件复发。

关键词(KeyWords)： 缺血性脑卒中;二级预防;血小板;血压;糖尿病

Abstract:

Keywords:

基金项目(Foundation): “十一五”国家科技支撑计划重大项目(2006BAI04A02)

作者(Authors): 王琪;赵红;黄燕;付于;

DOI: 10.13463/j.cnki.jlzyy.2009.03.044

参考文献(References)：

• [1] Billeci AM, Paciaroni M, Caso V, et al. Hormone replacement therapy and stroke [ J ]. Current Vascular Pharmacology. 2008, 6(2) : 112-123．
• [2] Emre U, Rantanen K.Tatlisumak T. Antithrombotic treatment in the prevention of ischemic stroke [J]. Current Drug Targets.2007,8(7) : 817-823．
• [3] 王力,张茁.缺血性脑卒中二级预防的循证医学证据[J].中华老年心脑血管病杂志,2007,9(8) :574-576．
• [4] Seok JI,Joo IS,Yoon JH,et al. Can aspirin resistance be clinically predicted in stroke patients? [ J]. Clinical Neurology And Neurosurgery.2008,110(2) : 110-116．
• [ 5 ] Cervera A, Tassies D, Obach V, et al. The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepre-sented in patients with recurrent stroke regardless of aspirin therapy [J]. Cerebrovascular Diseases (Basel, Switzerland). 2007,24(2-3) : 242-246．
• [6] The ESPS group. The European stroke prevention study (ESPS):principal end-point[J]. Lancet, 1987,14:5-14．
• [7] Davis SM,Donnan GA. Secondary prevention for stroke after CAPRIE and ESPS-2． Opinion 1[J]. Cerebrovasc Dis, 1998,87:73-75．
• [8] Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials[ J]. Stroke, 2005,36:162-168．
• [9] The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT) : randomised controlledtrial [ J ]. Lancet, 2006,367:1665-1673．
• [ 10 ] Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial(PRoFESS) [J].Cerebrovasc Dis, 2007,23:368-380．
• [11] 林豪杰,汪昕.缺血性脑卒中二级预防药物干预的循证医学证据[J].中华老年心脑血管病杂志,2008,10(1) :4-6．
• [12] SPORTIF Executive Steering Committee for the SPORTIF V investigators . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial [ J ].JAMA, 2005,293: 690-698．
• [13] Akins P,Feldman HA,Zoble R,et al. Secondary stroke prevention with Ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF Ⅲ and Ⅴ clinical trials[ J].Stroke, 2007,38:874-880．
• [14] The ESPIRIT Study Group. Medium intensity oral anticoagulant versus aspirin after cerebral ischeamia of arterial origin (ESPIRIT) : a randomised controlled trial [ J ]. Lancet Neurol, 2007, 6:115-124．
• [15] Xu G,Liu X,Zhu W, et al. Feasibility of treating hyperfibrino-genemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention [J]. Blood Coagulation & Fibrinolysis, 2007,18(2) : 193-197．
• [16] Sacco RL, Adams R,Albers G,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from American Heart Association/American Stroke Association Council on stroke:co-sponsored by the Council of Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline[J].Stroke,2006,37:577-617．
• [ 17 ] PROGRESS Collaborative Group. Randomised trial of a perindo-pril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack[ J] . Lancet,2001,29(358) :1033-1041．
• [18] Lawes CMM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews [ J]. Stroke, 2004, 35:1024-1033．
• [ 19 ] Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study(MOSES)[J] .Stroke,2005,36:1218-1226．
• [20] Amarenco P,Bogousslavsky J,Callahan A,et al. High-dose atorvastatin after stroke or transient ischemic attack [ J ]. N Engl J Med,2006,355:549-559．
• [21 ]Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglita-zone in patients with type 2 diabetes with or without previous stroke[J] .Nepal Medical College Journal.2007,9(2) :88-92．
• [22] Beg M,Nizami A,Singhal KC,et al.Role of serum fibrinogen in patients of ischemic cerebrovascular disease [ J ]. Nepal Medical College Journal.2007,9(2) :88-92．
• [ 23 ] Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis[J].Stroke,2003,34:2475-2481．
• [24] Maasland L, Koudstaal PJ, Habbema JD, et al. Knowledge and understanding of disease process, risk factors and treatment modalities in patients with a recent TIA or minor ischemic stroke [ J ]. Cerebrovascular Diseases ( Basel, Switzerland), 2007,23 (5-6) :435-440．
• [25] Leoo T,Iindgren A,Petersson J,et al.Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology(RESQUE) Study [J]. Cerebrovascular Diseases (Basel, Switzerland) ,2008,25(3) :254-260．